Nucleoside News and Research

RSS

Combating COVID cytokine storm with targeted nucleic acid therapies

Researchers examine current nucleic acid-based treatments against COVID-19 and their methods of action.

6 Mar 2022

Adenosine receptor agonists provide therapeutic target in mouse SARS-CoV-2 infection

A new study describes the efficacy of adenosine receptor agonists in the treatment of SARS-CoV-2 infection.

2 Mar 2022

Study finds MK-4482 inhibits replication of multiple SARS-CoV-2 variants of concern in Syrian hamster COVID-19 model

Researchers found that an antiviral drug, was effective against SARS-CoV-2 variants, including the recently emerged Omicron variant, in Syrian hamsters.

1 Mar 2022

Molecular insights on the possible connection of SARS-CoV-2 and nicotinic acetylcholine receptors

A recent study assessed the mechanism by which SARS-CoV-2 Omicron and Alpha VOCs inhibit the SARS-CoV-2 spike protein and mitigate the risk of a multisystem inflammatory syndrome in children.

28 Feb 2022

The in vitro selection of a remdesivir-resistant SARS-CoV-2 mutation

Researchers select and study an RDV-resistant virus by serial passaging of wild type SARS-CoV-2 in the presence of increasing concentrations of RDV.

15 Feb 2022

Antiviral activity assessment of remdesivir against 10 current and former SARS-CoV-2 variant clinical isolates

A new study published demonstrated the in vitro potencies of RDV and GS-441524 through PRA, and nucleoprotein ELISA against SARS-CoV-2 and other VOC/VOIs isolates with specific substitutions in Nsp12.

15 Feb 2022

RNA capping mechanism of SARS-CoV-2 unveiled

In a recent study posted to the bioRxiv* preprint server, researchers elucidated the mechanism of ribonucleic acid (RNA) capping in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2).

14 Feb 2022

Researchers identify a powerful combination of antivirals to treat COVID-19

Researchers at the University of Maryland School of Medicine and University of Pennsylvania Perelman School of Medicine have identified a powerful combination of antivirals to treat COVID-19.

14 Feb 2022

Properties and pharmacokinetics an oral drug candidate for COVID-19 treatment

Researchers studied the preclinical PK) and in vitro ADME properties of GS-441524, a potential oral drug for COVID-19 treatment.

10 Feb 2022

Researchers identify a potent new combination of antiviral drugs to combat SARS-CoV-2

The recent success of Paxlovid has encouraged researchers to develop new anti-covid drugs. With this in mind, scientists from the University of Pennsylvania have been investigating a new synergistic treatment. Their research is released early as an unedited version of the manuscript to be published in the journal Nature.

9 Feb 2022

Study opens the door to a new approach to attacking herpesviruses

A new study published this week in mBio, an open access journal of the American Society for Microbiology, has opened the door to a new approach to attacking herpesviruses.

25 Jan 2022

From laboratory to clinic - Nanotechnology-enabled mRNA COVID-19 vaccines

In a recently published article in the journal Nano-Micro Letters, scientists have provided an in-depth review on the application and benefits of nanotechnology in the development of coronavirus disease 2019 (COVID-19) vaccines.

7 Jan 2022

WHO lists the Comirnaty COVID-19 mRNA vaccine for emergency use

The World Health Organization today listed the Comirnaty COVID-19 mRNA vaccine for emergency use, making the Pfizer/BioNTech vaccine the first to receive emergency validation from WHO since the outbreak began a year ago.

2 Jan 2022

New oral pill for COVID-19 home treatment

As cases and hospitalizations continue to rise in many countries, new treatments are being sought to arrest the progression of the disease, preventing severe illness and death or disability. One such is the small molecule molnupiravir, the focus of a new research paper.

20 Dec 2021

New mRNA vaccine platform provides stronger protection against SARS-CoV-2 delta variant

A group of researchers from various institutions developed a nucleoside-modified mRNA vaccine that encodes the SARS-CoV-2 N protein (mRNA-N) and is formulated in lipid nanoparticles for this investigation (LNP).

14 Dec 2021

Newly discovered hormone may play a key role in the development of type 1 and type 2 diabetes

A newly discovered hormone named fabkin helps regulate metabolism and may play an important role in the development of both type 1 and type 2 diabetes, according to research led by the Sabri Ülker Center for Metabolic Research at Harvard T.H. Chan School of Public Health.

12 Dec 2021

New hormone may play a key role in the development of type 1 and type 2 diabetes

8 Dec 2021

Study suggests efficacy of SARS-CoV-2 main protease inhibitors is not compromised in current COVID-19 variants

A new study has focussed on assessing the Mpro mutants of newly emerged SARS-CoV-2 variants.

2 Dec 2021

First long-acting injectable HIV treatment appraised and approved by NICE

ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc, with Pfizer Inc. and Shionogi Limited as shareholders, is pleased to announce that eligible people living with Human Immunodeficiency Virus (HIV) in England and Wales will soon have routine access to Vocabria (cabotegravir long-acting injection) developed by ViiV Healthcare in combination with Rekambys (rilpivirine long-acting injection), developed by Janssen Sciences Ireland UC (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

19 Nov 2021

Study shows 90.7% efficacy for the BNT162b2 COVID vaccine in 5-11 year-olds

A new study evaluates the safety, immunogenicity, and efficacy of the BNT162b2 in children who were 5 to 11 years of age.

11 Nov 2021